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Abstract
Three different cancers predominantly occur at the gastro-oesophageal junction: squamous
cell carcinomas of the distal oesophagus, adenocarcinomas of the distal oesophagus (Barrett’s
carcinomas), and adenocarcinomas of the gastric cardia. The aim of the present study was
to investigate how, and to what extent, Barrett’s carcinoma differs from adenocarcinoma of
the gastric cardia on the one hand and squamous cell carcinoma of the distal oesophagus on
the other, with respect to chromosomal aberrations and related gene expression. The present
study analysed 14 squamous cell carcinomas, 24 Barrett’s carcinomas, and 16 carcinomas of
the gastric cardia. Comparative genomic hybridization revealed chromosomal abnormalities
in all cases. Typical chromosomal aberrations for the squamous cell carcinoma type were
gains at 3q and 11q13, and losses at 3p, 4q, 9p, 11q, and 13q. In contrast, typical copy number
changes for both cardiac and Barrett’s adenocarcinomas were gains at 2q, 7p, and 13q, and
losses at 17p. High-level amplification occurred in all three groups, but its frequency in the
cardiac carcinomas was lower than in the other two groups. In conclusion, squamous cell
carcinomas are characterized by chromosomal aberrations which are distinct from those
seen in carcinomas of the gastric cardia and in Barrett’s adenocarcinomas. With respect
to Barrett’s cancer, the chromosomal aberrations more closely reflect the adenocarcinoma
phenotype than the squamous origin of the epithelium. Copyright  2002 John Wiley &
Sons, Ltd.
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Introduction
Adenocarcinoma of the stomach has been the leading
cause of cancer death worldwide through most of the
20th century. It now ranks second only to lung cancer,
with an estimated 755 500 new cases diagnosed annu-
ally around the world. The incidence of this disease has
gradually decreased in many parts of the world, princi-
pally because of changes in H. pylori prevalence, diet,
food preparation, and other environmental factors. In
contrast, the number of patients with Barrett’s cancer
(BC) has increased markedly since the mid-1980s [1].
A third type of carcinoma occurring in this area is
the squamous cell carcinoma of the distal oesopha-
gus (eSCC). Although these three types of malignan-
cies occur at the same anatomical site, they differ
greatly with respect to their epidemiology and risk
factors. The incidence of oesophageal adenocarcinoma
has recently risen dramatically in Western popula-
tions, whereas the incidence of squamous cell car-
cinomas has remained relatively steady [2]. Reflux
disease has been suggested as an aetiological factor
not only in oesophageal adenocarcinoma, but also in
cancer of the gastric cardia (CC) [3]. Other risk fac-
tors include smoking [4], increased fat intake [5], and
obesity [6], whereas colonization with H. pylori has
been suggested to protect against gastro-oesophageal
reflux and Barrett’s oesophagus [7]. For squamous
cell carcinoma of the distal oesophagus, smoking and
alcohol consumption are aetiological factors. The his-
tology of adenocarcinomas of the gastric cardia and
squamous cell carcinomas of the distal oesophagus
matches with the original epithelium of the stomach
Copyright  2002 John Wiley & Sons, Ltd.
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and oesophagus, respectively, which are distinctly
different. For Barrett’s carcinomas, another situa-
tion exists. These tumours show histology that dif-
fers from that of the original epithelium, since it
is preceded by a process of metaplasia, in which
the squamous epithelium is replaced with metaplastic
columnar epithelium.
The aim of the present study was to investigate how,
and to what extent, Barrett’s cancer compares with
adenocarcinoma of the gastric cardia on the one hand
and squamous cell carcinoma of the distal oesopha-
gus on the other, in terms of chromosomal aberrations
and related gene expression. To this end, we anal-
ysed 16 adenocarcinomas of the gastric cardia, 24
Barrett’s carcinomas, and 14 squamous cell carcino-
mas of the distal oesophagus by comparative genomic
hybridization (CGH). This technique allows the detec-
tion of chromosomal gains and losses throughout the
whole genome in a single experiment, using DNA
isolated from either frozen or formaldehyde-fixed,
paraffin-embedded tissue [8]. In order to analyse the
effect of amplifications at chromosomes 11q13 and
17q12–21 on the expression of genes in these regions,
immunohistochemistry on tissue sections was per-
formed with antibodies against cyclin D1 and Her-
2/Neu, respectively.
Material and methods
Material
A total of 54 patients with CC (n = 16), BC (n = 24)
or eSCC (n = 14), diagnosed by endoscopy with
biopsy sampling and subsequently treated by partial
or total gastrectomy or oesophagectomy, respectively,
were included in the study. The Barrett’s cancers were
obtained from the Departments of Pathology of the VU
University Medical Centre and the Academic Medical
Centre, both in Amsterdam. All cases were selected
according to strict criteria, based on macroscopic [by
means of photographic images (Figure 1)] and micro-
scopic re-evaluation. The tumours from the Academic
Medical Centre were all macroscopically adenocarci-
nomas of the distal oesophagus, in which surround-
ing Barrett’s mucosa could be identified on light
microscopy, by the presence of specialized columnar
epithelium containing goblet cells (intestinal metapla-
sia). In the samples from the Department of Pathology
at the VU University Medical Centre, a background
of intestinal metaplasia could not be demonstrated in
every case on review of the slides. However, the study
only included cases in which careful re-examination
of the high-quality macroscopic photographs, taken
of each resection specimen as a standard procedure,
allowed an unambiguous classification. In this way,
only cases with at least 75% of the tumour situated
in either the cardia or the oesophagus were included.
Clinical and patient characteristics are summarized in
Table 1.
Both frozen and formaldehyde-fixed, paraffin-
embedded material was used in this study. Tissue
blocks with the highest concentration of tumour cells
were selected for DNA isolation. For each case, a
tumour area of approximately 5 × 5 mm containing
more than 75% tumour cells was outlined on a
haematoxylin and eosin (H&E) slide, avoiding areas
with a high concentration of inflammatory or other
non-tumour cells. In 10–15 consecutive haematoxylin-
stained tissue sections of 10 µm thickness, the
corresponding area was scraped off with a surgical
Figure 1. (A) Macroscopic image of a partial oesophagogastrectomy specimen showing a tumour in the distal part of the
oesophagus above the Z-line, classified as a Barrett’s adenocarcinoma. (B) Macroscopic image of a partial gastrectomy specimen
(without oesophagus) showing a tumour in the upper part of the stomach, classified as an adenocarcinoma of the gastric cardia
Copyright  2002 John Wiley & Sons, Ltd. J Pathol 2003; 199: 157–165.
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Table 1. Clinical and pathological patient characteristics
Sex Stage∗
Histological
differentiation
Type n
Male
(n)
Female
(n)
Mean age
(range), years T1–T2 T3–T4 Well Moderate Poor Laure`n type†
SCC 14 6 8 64 (40–75) n = 6 n = 7 n = 0 n = 3 n = 11 —
BC 24 20 4 62 (28–73) n = 12 n = 14 n = 4 n = 8 n = 12 —
CC 16 13 3 63 (34–85) n = 4 n = 12 n = 0 n = 7 n = 9 15 intestinal 1 diffuse
∗ For one SCC case, the stage was not possible to judge, since this was a mucosectomy sample.
† For cancers of gastric cardia only.
blade. As a control, two H&E slides were taken
following the ‘sandwich’ method. DNA isolation
with the Qiamp Tissue Kit (Qiagen GmbH, Hilden,
Germany) was performed as described previously [8].
Methods
Comparative genomic hybridisation (CGH)
CGH was performed as described before [8]. Eight
to 12 metaphases were recorded and analysed. This
yielded relative copy number karyotypes with mean
fluorescence ratios and their 95% confidence inter-
vals (CIs) plotted along the ideograms of the corre-
sponding chromosomes. Deviations from normal were
interpreted as gains or losses when the mean fluores-
cence ratios were above 1.2 or below 0.8, respectively,
provided that the 95% confidence interval around the
mean fluorescence ratio did not include 1.0. An event
was defined as gain or loss of (part of) a chromo-
somal arm. Two or more distinct sub-regional copy
number changes affecting the chromosomal arm were
counted as separate events. Chromosomal aberrations
with frequencies of 35% or higher were considered
non-random changes associated with oesophageal or
gastric cancer (Table 2).
Immunohistochemical staining
In order to analyse the effect of amplifications at chro-
mosomes 11q13 and 17q12–21 on the expression of
genes in these regions, immunohistochemistry on tis-
sue sections was performed with antibodies against
cyclin D1 and Her-2/Neu, respectively. One CC could
not be analysed immunohistochemically because of
lack of material. Immunohistochemistry for cyclin D1
was performed as described before, with minor mod-
ifications [9]. In short, 4 µm sections were cut from
paraffin-embedded tissue and mounted on Superfrost
Plus slides (Menzel-Gla¨ser, Germany). The sections
were deparaffinized, blocked for endogenous peroxi-
dase activity, and antigen retrieval was performed by
heating the slides in an autoclave in citrate buffer.
The primary antibody against cyclin D1 (DCS-6,
Neomarkers, Labvision, Fremont, CA, USA) was
used in a 1 : 400 dilution. Slides were incubated
Table 2. Statistical evaluation of the differences of the most frequent aberrations between
the squamous cell carcinomas, Barrett’s adenocarcinomas, and cardiac adenocarcinomas
p value
CGH
event
eSCC
(n = 14)
BC
(n = 24)
CC
(n = 16)
eSCC
vs CC
eSCC
vs BC
SCC vs
adeno
1q+ 43% 33% 63% NS NS NS
2q+ 7% 42% 38% 0.05 0.02 0.02
3p− 64% 4% 19% 0.01 <0.001 <0.001
3q+ 79% 38% 50% NS 0.01 0.02
4q− 43% 8% 19% NS 0.01 0.02
6q+ 36% 33% 44% NS NS NS
7p+ 14% 46% 50% 0.04 0.05 0.03
7q+ 36% 54% 50% NS NS NS
8q+ 50% 54% 56% NS NS NS
9p− 50% 17% 19% NS 0.03 0.02
11q− 50% 13% 31% NS 0.01 0.03
11q13+ 57% 17% 31% NS 0.01 0.02
13q− 50% 4% 0% 0.001 0.001 <0.001
13q+ 14% 42% 44% NS NS 0.06
17p− 14% 58% 38% NS 0.008 0.02
18q− 36% 46% 25% NS NS NS
20q+ 21% 38% 44% NS NS NS
p values (two-sided Pearson chi-square test) are given pairwise. The p values in the last column give
the differences between the squamous cell carcinomas versus the adenocarcinomas (BC and CC).
Copyright  2002 John Wiley & Sons, Ltd. J Pathol 2003; 199: 157–165.
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Figure 2. Overview of the genetic changes detected by CGH in 16 adenocarcinomas of the gastric cardia (A), 24 Barrett’s
carcinomas (B), and 14 squamous cell carcinomas of the distal oesophagus (C). Bars on the left of each chromosomal ideogram
represent a loss, and on the right a gain of the corresponding part of the chromosome in a particular tumour. Thick lines represent
amplifications
overnight with the primary antibodies at 4 ◦C. Subse-
quently, slides were incubated with biotinylated rab-
bit anti-mouse antibody (1 : 200), followed by incuba-
tion with 1 : 100 streptavidin-biotinylated horseradish-
peroxidase complex. 3,3′-Diaminobenzidine was used
as the chromogen and haematoxylin as the counter-
stain.
Immunohistochemistry (IHC) for Her-2/Neu was
performed in the Ventana ES, using a monoclonal anti-
body [anti-C-erbB-2 (Her-2/Neu), Ventana Medical
Copyright  2002 John Wiley & Sons, Ltd. J Pathol 2003; 199: 157–165.
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Systems, Inc, Tucson, AZ, USA] to Her-2/Neu, an
oncoprotein that is localized on the cell membrane,
and occasionally in the cytoplasm of some neoplastic
cells. The Ventana ES Immunohistochemistry Stain-
ing System is a microprocessor-controlled system for
performing routine IHC. Paraffin-embedded tissue sec-
tions of 4 µm were cut and deparaffinized. Antigen
retrieval was done by heating the slides in an auto-
clave in citrate buffer. The incubation time for the
primary antibody was 32 min. A known positive duc-
tal breast carcinoma was used as a positive control,
while a negative control was obtained by omitting the
primary antibodies from the staining procedure.
The intensity of nuclear and/or membranous stain-
ing, for cyclin D1 or Her-2/Neu, respectively, was
scored as negative or positive on microscopic exami-
nation by two observers.
Statistical analysis
The differences in the incidence of chromosomal
aberrations per diagnostic category were pairwise
tested for significance using the two-sided Pearson chi-
square test. p values less than 0.05 were considered
significant. Significance of differences in the means
of the total number of CGH events, gains, losses,
and high-level gains per tumour in three diagnostic
categories was tested pairwise by Student’s t-test.
Results
Comparative genomic hybridization revealed chromo-
somal abnormalities in all cases. The mean number
and standard deviation of events in eSSC, BC, and CC
was 14 (8.3), 12 (5.8), and 14 (8.0), respectively (NS).
In addition, the numbers of gains, losses, and high-
level amplifications were similar between the three
groups. An overview of the CGH results in all three
categories (n = 54) is shown in Figures 2A, 2B, and
2C. The most frequent aberrations in eSCC are, in
descending order, gains at 3q (79%), 11q13 (57%),
8q (50%), 1q (43%), 6q (36%), and 7q (36%), and
losses at 3p (64%), 9p (50%), 11q (50%), 13q (50%),
4q (43%), and 18q (36%). In BC, frequent gains were
found at 7q (54%), 8q (54%), 7p (46%), 2q (42%), 13q
(42%), 3q (38%), and 20q (38%), and losses at 17p
(58%), and 18q (46%). In CC, the most frequent gains
were at 1q (63%), 8q (56%), 3q (50%), 7p (50%),
7q (50%), 6q (44%), 13q (44%), 20q (44%), and 2q
(38%), and loss at 17p (38%) (Table 2).
The main differences in the patterns of chromosomal
aberrations were found between eSCC on the one
hand and the adenocarcinomas (BC and CC) on
the other. Typical chromosomal aberrations for the
squamous cell carcinoma type were gains at 3q and
11q13, and losses at 3p, 4q, 9p, 11q, and 13q. In
contrast, typical copy number changes for (BC and
CC) adenocarcinomas were gains at 2q, 7p, and
13q, and losses at 17p (Table 2). One chromosomal
aberration did show a significant difference between
BC and CC (gain of 4p), but this gain occurred at a
rather low frequency (three times in CC; none in BC).
High-level amplification occurred in all three
groups, but its frequency in CC was lower than in
the other two groups. From a biological perspective
there was a high incidence of recurrent amplifications,
although the absolute numbers were too low for
reliable statistical analysis. Nevertheless, a certain
specificity for diagnostic categories could be noted
here (Table 3); for example, in the eSCC group,
amplification of 11q13 occurred in 50% of the cases,
compared with only a single case in BC and none
in CC. In addition, amplification of 7q21–22 and
17q12–21 occurred preferentially in BC (25% and
21%, respectively), versus 0% for these regions in CC
and 7% and 0%, respectively, in eSCC.
Overexpression of cyclin D1 is shown in 11/14
eSCCs (79%), 7/24 BCs (29%), and 6/15 CCs (40%)
by immunohistochemistry (Table 4). All but one of
the cases with amplification of 11q13 showed overex-
pression at the protein level, while in one eSCC case
we detected amplification by CGH without protein
overexpression. Her-2/Neu overexpression was seen
in only 1/11 (7%) eSCCs, 10/24 (42%) BCs, and 3/15
(20%) CCs. Of BC with protein overexpression, four
cases were seen with and six without amplification.
One BC with 17q12–21 amplification did not show
protein overexpression. Finally, in all three CCs show-
ing Her-2/Neu protein overexpression, we could not
detect amplification of the chromosomal locus.
Discussion
Patients with cancer of the cardia more closely resem-
ble those with Barrett’s carcinoma than those with
cancers of the distal stomach, in terms of sex and
racial characteristics, frequency of reflux symptoms,
and frequency of associated atrophic gastritis. Disease
behaviour and survival in Barrett’s and gastric car-
diac cancer also appear very similar [10]. However,
Barrett’s cancer differs from cancers of the gastric car-
dia with respect to certain epidemiological parameters
that could reflect independent carcinogenetic mecha-
nisms. There is a higher proportion of males among
the patients with carcinoma of the cardia. In addition,
patients with cardiac cancer more frequently have a
history of heavy smoking and alcohol intake, whereas
those with Barrett’s carcinoma are much more likely
to have hiatus hernias [11]. Morphologically, Barrett’s
carcinoma and cardiac cancer are virtually identical,
and clearly different from squamous cell carcinoma of
the oesophagus, although Barrett’s carcinoma arises in
squamous epithelium through a phase of metaplasia.
In clinical practice, adenocarcinomas of the gas-
tric cardia and those arising in the distal oesophagus,
the Barrett’s carcinomas, were in the past often clas-
sified under the single heading of adenocarcinoma
Copyright  2002 John Wiley & Sons, Ltd. J Pathol 2003; 199: 157–165.
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Table 3. High-level gains and candidate genes located at these loci
High-level
gain
eSCC
(n = 14)
BC
(n = 24)
CC
(n = 16)
Candidate
genes
2q11.2–12 1 (7%) — —
4p16 2 (14%) — — Cyclin G-associated kinase
(GAK)
Fibroblast growth factor
receptor 3 (FGFR3)
Zinc finger protein 141
(ZNF141)
HGF activator (HGFAC)
4q27 — 1 (4%) — Cyclin A
6p12–21.2 1 (7%) 2 (8%) 1 (6%) Vascular endothelial growth
factor A (VEGFA)
Protein-tyrosine kinase-7
(PTK7)
6q22 1 (7%) — — MYB oncogene, ROS
oncogene
7p11.2–13 — 1 (4%) 1 (6%) Epidermal growth factor
receptor (EGFR)
7p22 1 (7%) — —
7q21–22 1 (7%) 6 (25%) — Hepatocyte growth factor
(HGF)
Nerve growth
factor-inducible (VGF)
MUC 3A, 11, and 12
7q22–31 — 1 (4%) 3 (19%) C-Met (HGF-receptor)
8p11.2–12 2 (14%) — — Fibroblast growth factor
receptor 1 (FGFR1)
8p22–23 — 1 (4%) 3 (19%) Platelet-derived growth
factor receptor-like
Cathepsin B
9q31–33 — 1 (4%) —
11p14 — 1 (4%) —
11p11–13 1 (7%) 1 (4%) — Neurite growth-promoting
factor-2
11q13 7 (50%) 1 (4%) — Fibroblast growth factor 3
(FGF3)
Fibroblast growth factor 4
(FGF4)
Cyclin D1
EMS1 oncogene
PAK1
11q23–24 — — 1 (6%)
12p11.2–12 1 (7%) 2 (8)% — Retinoblastoma-binding
protein-2
12q14 1 (7%) — — MDM2
13q12–13 — 1 (4%) — Fibroblast growth factor 9
(FGF9)
BRCA2
13q13–14 — 1 (4%) — Rb
13q21–22 1 (7%) 1 (4%) —
17q12–21 — 5 (21%) — HER-2-Neu (ERBB2)
Nerve growth factor
receptor (NGFR)
Fibroblast growth factor 11
(FGF11)
18p 1 (7%) — 1 (6%) Yes1
19p13.1 — 1 (4%) —
19q13.1 — 2 (8%) 2 (13%) Transforming growth factor
beta 1 (TGFB1)
Cyclin E
22q11.2 — 1 (4%) —
of the gastro-oesophageal junction. However, interna-
tional classifications do discriminate between cardiac
and oesophageal adenocarcinomas. This discrimina-
tion appears to be of relevance since these tumours
differ in time with respect to changes in incidence and
may also differ with respect to their underlying aeti-
ology. In clinical practice, differentiation can in most
cases be made on parameters such as the location of
Copyright  2002 John Wiley & Sons, Ltd. J Pathol 2003; 199: 157–165.
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Table 4. Correlation between protein expression of cyclin D1 and Her-2/Neu and amplification of their chromosomal loci
eSCC
(n = 14)
Barrett’s
(n = 24)
Cardia
(n = 15)∗ Totals
11q13
amplification
11q13
amplification
11q13
amplification
11q13
amplification
Yes No Totals Yes No Totals Yes No Totals Yes No Totals
Cyclin D1
overexpression
Yes 6 5 11 1 6 7 — 6 6 7 17 24
No 1 2 3 — 17 17 — 9 9 1 28 29
Totals 7 7 14 1 23 24 0 15 15 8 45 53
17q12–21
amplification
17q12–21
amplification
17q12–21
amplification
17q12–21
amplification
Yes No Totals Yes No Totals Yes No Totals Yes No Totals
Her-2/Neu
overexpression
Yes — 1 1 4 6 10 — 3 3 4 10 14
No — 13 13 1 13 14 — 12 12 1 38 39
Totals 0 14 14 5 19 24 0 15 15 5 48 53
∗ One CC case was not investigated by immunohistochemistry since tissue was no longer available.
the bulk of the tumour and the presence or absence of
surrounding Barrett’s mucosa. Discrimination between
these two tumour types is a key issue in the present
study. We therefore carefully selected Barrett’s can-
cers according to strict criteria, in order to arrive at
an unambiguous classification. Only in this way can a
sound comparison be made of the chromosomal aber-
rations in these two types of cancer.
In the past, CGH studies have yielded indications for
different patterns of chromosomal aberration between
squamous cell carcinoma and adenocarcinoma, as
was the case in the present study. Squamous cell
carcinomas frequently show gains at 3q, 5p, 8q, 11q13,
and17q; losses at 3p, 4p, 5q, 11qter, 13q, and 18q;
and high-level gains at 11q13, and 3q24-qter, while
adenocarcinomas frequently show gains at 1q, 8q, 13q,
and 20, and losses at 1p, 8p, 9p, and 17p [12–24]. This
could indicate that different cell biological pathways
need to be (de-) activated, or that the same pathway
can be deregulated via different genetic changes, for
tumour progression in squamous cell epithelium and
columnar epithelium. An intriguing question is how
tumours would behave that arise through a phase
of metaplasia. The present study demonstrates that
at the chromosomal level, adenocarcinomas of the
gastric cardia and Barrett’s carcinomas show close
similarities. When comparing the Barrett’s cancers to
the squamous cell carcinomas of the distal oesophagus,
there is little to remind us of a common origin, the
epithelial stem cell.
This study is the first to compare squamous cell car-
cinomas, Barrett’s carcinomas, and cardiac carcinomas
in a single series of experiments. This is important
because although CGH in itself is a straightforward
technique, comparison of data from different studies
may be influenced by different experimental condi-
tions as well as by different strategies for interpreting
the results. A sound comparison of chromosomal aber-
rations in different sets of tumours can therefore only
come from a study that has been designed to eliminate
these sources of bias.
We found significant differences in chromosomal
aberrations between the squamous cell carcinomas
and the adenocarcinomas (both Barrett’s and cardiac).
Gains at 11q13 and 3q, and losses at 3p, 4q, 9p,
11q, and 13q were found more often in the squamous
cell carcinomas. Gains at 2q, 7p, and 13q, and
loss at 17p seemed to occur predominantly in the
adenocarcinomas. Except for 4p gain, we did not
detect any relevant differences in gains and losses
between the Barrett’s carcinomas and the cardiac
cancers. Loss of 14q31–32 has been suggested to
have some discriminative power between cardiac and
Barrett’s cancer [25,26], but the data of the present,
larger study and the LOH study of Yanagi et al. could
not confirm this [27].
However, Barrett’s carcinomas shared with the
squamous cell carcinomas a higher incidence of ampli-
fications than the cardiac cancers. 11q13 is ampli-
fied in 50% of the squamous cell carcinomas and
almost never in the other two groups. In addition,
the frequency of cyclin D1 overexpression was also
highest in the squamous cell carcinomas (79%). Never-
theless, cyclin D1 protein overexpression was detected
in 29% and 40% of the Barrett’s and the cardiac
carcinomas, respectively. In contrast, 17q12–q21 was
only found to be amplified in the Barrett’s carci-
nomas, while Her-2/Neu positivity was also highest
in the Barrett’s carcinomas (42%). Interestingly, the
one squamous cell carcinoma with Her-2/Neu overex-
pression appeared on re-examination also to harbour
glandular differentiation and was thus classified as an
adenosquamous variant. In addition, the relatively high
frequency of 7q and 17q amplifications in Barrett’s
Copyright  2002 John Wiley & Sons, Ltd. J Pathol 2003; 199: 157–165.
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Figure 3. Relationship between genotype and phenotype in carcinogenesis (see text)
cancers compared with cardiac cancers could be an
argument in favour of Barrett’s cancer being a separate
entity from cancers of the gastric cardia.
As to the association between gene expression
and amplification, different patterns occurred. Gene
amplification status matched with immunohistochem-
ically detected protein expression for cyclin D1 in
66% (35/53) of cases and for Her-2/Neu in 79%
(42/53). The finding of one squamous cell cancer
showing 11q13 amplification without cyclin D1 over-
expression, as well as one Barrett’s cancer showing
17q12–21 amplification without Her-2/Neu overex-
pression, could mean that still other oncogenes at
these chromosomal regions are involved in the devel-
opment of these tumours (Table 3). Conversely, in
32% (17/53) of cases cyclin D1 overexpression and in
19% (10/53) of cases Her-2/Neu overexpression was
found without amplification of the corresponding chro-
mosomal regions, indicating that other mechanisms
than gene amplification can also disrupt these biolog-
ical pathways, such as amplification or mutation of
upstream regulators.
The relationship between the metaplastic pheno-
type and genetic alterations remains intriguing from a
pathogenetic point of view. When metaplastic change
occurs early in the pathogenesis of cancer, as in the
case of intestinal metaplasia in Barrett’s oesopha-
gus, major differences are found between ‘metaplas-
tic’ and ‘non-metaplastic’ cancers, as shown in the
present study, although some characteristics remain,
such as the higher tendency to high-level amplifica-
tions. Similar findings have been made for adeno-
carcinomas and squamous cell carcinomas of both
the uterine cervix [28] and the lung [29–31]. At the
other end of the spectrum, a change in phenotype
can occur at a stage when a cancer has already
developed, such as adenosquamous carcinomas and
carcinosarcomas. In such truly metaplastic carcino-
mas, the distinct components may show huge phe-
notypic, histological, ultrastructural, and immunohis-
tochemical differences, but genotypically these dif-
ferent tumour components may show marked resem-
blances (Figure 3) [32]. This indicates that much of
the genotype–phenotype relationship still remains to
be resolved.
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